Cargando…

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)

BACKGROUND: Weight gain associated with integrase strand transfer inhibitors (INSTI) has been well documented among patients with HIV. However, recent reports suggest that the observed weight gain among patients who switch to INSTIs may be associated in part with their pre-switch regimen. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Cutshaw, Melissa Klein, Harding, Mahmoud, Davenport, Clemontina A, Okeke, Nwora Lance
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676934/
http://dx.doi.org/10.1093/ofid/ofad500.1401
_version_ 1785150011016740864
author Cutshaw, Melissa Klein
Harding, Mahmoud
Davenport, Clemontina A
Okeke, Nwora Lance
author_facet Cutshaw, Melissa Klein
Harding, Mahmoud
Davenport, Clemontina A
Okeke, Nwora Lance
author_sort Cutshaw, Melissa Klein
collection PubMed
description BACKGROUND: Weight gain associated with integrase strand transfer inhibitors (INSTI) has been well documented among patients with HIV. However, recent reports suggest that the observed weight gain among patients who switch to INSTIs may be associated in part with their pre-switch regimen. METHODS: We conducted retrospective analyses of a 50% sample of all treatment-experienced patients who switched to second-generation INSTI containing regimen (bictegravir/dolutegravir) at the Duke Adult Infectious Diseases Clinic (Durham, NC, USA) between 1 January 2014 and 31 December 2021. Covariates included sex at birth, age, race, ethnicity, pre-switch regimen, body mass index (BMI), CD4 count and HIV-1 viral load. All weights documented within 24 months from regimen switch were included. Outcomes of interest were percent change in weight and absolute weight change. Ordinary least squares was used to obtain average percent weight change from baseline, adjusted for covariates. RESULTS: Overall, 339 persons were included in the analyses. Cohort demographics were: median age 51.2 (interquartile range 44.4, 57.6), 73% male sex at birth, 56% Black, 4% Hispanic ethnicity. At regimen switch, median CD4 count was 671 (IQR 460-935), and 78% had a viral load < 200 copies/cc. Mean weight at regimen switch was 87.8 kg (standard deviation [SD] 22.1kg), and mean total weight change over 24 months post-switch was +1.3 kg (SD 7.1 kg). Overall, 28% of cohort members gained >5% of baseline body weight within 24 months of switch. Hispanic ethnicity (5.9% [95% CI 1.0, 10.7]) and BMI < 20 (3.7% [95% CI -0.3, 7.7]) were associated with post-switch weight gain. Only efavirenz-containing pre-switch regimens were significantly associated with weight gain over 24 months post-switch; EFV/FTC/TDF (3.1% [95% CI 0.2, 6.1]), all other EFV-containing regimens (6.3% [95% 0.1-12.4]). CONCLUSION: Pre-switch regimens containing efavirenz were significantly associated with weight gain after switch to second-generation INSTI-based regimens, consistent with findings from non-US based cohorts. DISCLOSURES: Nwora Lance Okeke, MD MPH, Gilead Sciences: Advisor/Consultant
format Online
Article
Text
id pubmed-10676934
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106769342023-11-27 1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI) Cutshaw, Melissa Klein Harding, Mahmoud Davenport, Clemontina A Okeke, Nwora Lance Open Forum Infect Dis Abstract BACKGROUND: Weight gain associated with integrase strand transfer inhibitors (INSTI) has been well documented among patients with HIV. However, recent reports suggest that the observed weight gain among patients who switch to INSTIs may be associated in part with their pre-switch regimen. METHODS: We conducted retrospective analyses of a 50% sample of all treatment-experienced patients who switched to second-generation INSTI containing regimen (bictegravir/dolutegravir) at the Duke Adult Infectious Diseases Clinic (Durham, NC, USA) between 1 January 2014 and 31 December 2021. Covariates included sex at birth, age, race, ethnicity, pre-switch regimen, body mass index (BMI), CD4 count and HIV-1 viral load. All weights documented within 24 months from regimen switch were included. Outcomes of interest were percent change in weight and absolute weight change. Ordinary least squares was used to obtain average percent weight change from baseline, adjusted for covariates. RESULTS: Overall, 339 persons were included in the analyses. Cohort demographics were: median age 51.2 (interquartile range 44.4, 57.6), 73% male sex at birth, 56% Black, 4% Hispanic ethnicity. At regimen switch, median CD4 count was 671 (IQR 460-935), and 78% had a viral load < 200 copies/cc. Mean weight at regimen switch was 87.8 kg (standard deviation [SD] 22.1kg), and mean total weight change over 24 months post-switch was +1.3 kg (SD 7.1 kg). Overall, 28% of cohort members gained >5% of baseline body weight within 24 months of switch. Hispanic ethnicity (5.9% [95% CI 1.0, 10.7]) and BMI < 20 (3.7% [95% CI -0.3, 7.7]) were associated with post-switch weight gain. Only efavirenz-containing pre-switch regimens were significantly associated with weight gain over 24 months post-switch; EFV/FTC/TDF (3.1% [95% CI 0.2, 6.1]), all other EFV-containing regimens (6.3% [95% 0.1-12.4]). CONCLUSION: Pre-switch regimens containing efavirenz were significantly associated with weight gain after switch to second-generation INSTI-based regimens, consistent with findings from non-US based cohorts. DISCLOSURES: Nwora Lance Okeke, MD MPH, Gilead Sciences: Advisor/Consultant Oxford University Press 2023-11-27 /pmc/articles/PMC10676934/ http://dx.doi.org/10.1093/ofid/ofad500.1401 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Cutshaw, Melissa Klein
Harding, Mahmoud
Davenport, Clemontina A
Okeke, Nwora Lance
1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
title 1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
title_full 1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
title_fullStr 1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
title_full_unstemmed 1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
title_short 1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
title_sort 1566. determinants associated with weight gain among persons with hiv who switch to integrase strand transfer inhibitors (insti)
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676934/
http://dx.doi.org/10.1093/ofid/ofad500.1401
work_keys_str_mv AT cutshawmelissaklein 1566determinantsassociatedwithweightgainamongpersonswithhivwhoswitchtointegrasestrandtransferinhibitorsinsti
AT hardingmahmoud 1566determinantsassociatedwithweightgainamongpersonswithhivwhoswitchtointegrasestrandtransferinhibitorsinsti
AT davenportclemontinaa 1566determinantsassociatedwithweightgainamongpersonswithhivwhoswitchtointegrasestrandtransferinhibitorsinsti
AT okekenworalance 1566determinantsassociatedwithweightgainamongpersonswithhivwhoswitchtointegrasestrandtransferinhibitorsinsti